Improved clinical outcomes for prostate cancer webinar
Enhanced dose escalation -- adding a brachytherapy boost to external beam radiation therapy -- is associated with superior PSA-RFS outcomes in intermediate risk prostate cancer patients compared with high-dose IMRT alone*. In this webinar our clinical expert, Prof. Razvan Galalae, MD, PhD, describes experiences in HDR brachytherapy for prostate cancer. Prof. Galalae is Associate Professor for Radiation Oncology at Christian-Albrechts-Univ. Kiel, Germany and Clinical Director at Interventional Particle Therapy, MedAustron Carbon Ion Center Vienna, Austria.
* Source: Deutsch et al. Brachytherapy 9 (2010) 313-318